Cutia Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Cutia Therapeutics' CEO is Lele Zhang, appointed in Sep 2019, has a tenure of 5.17 years. total yearly compensation is CN¥50.60M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth HK$339.79K. The average tenure of the management team and the board of directors is 2.5 years and 4.3 years respectively.

Anahtar bilgiler

Lele Zhang

İcra Kurulu Başkanı

CN¥50.6m

Toplam tazminat

CEO maaş yüzdesi	5.6%
CEO görev süresi	5.2yrs
CEO sahipliği	0.009%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Does Cutia Therapeutics (HKG:2487) Have A Healthy Balance Sheet?

Aug 30

A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487)

Jun 03

Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week

Apr 08

CEO Tazminat Analizi

Lele Zhang'un ücretlendirmesi Cutia Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥524m
Mar 31 2024	n/a	n/a	-CN¥1b
Dec 31 2023	CN¥51m	CN¥3m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥2b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥21m	CN¥4m	-CN¥556m
Dec 31 2021	CN¥27m	CN¥3m	-CN¥320m

Tazminat ve Piyasa: Lele's total compensation ($USD7.14M) is above average for companies of similar size in the Hong Kong market ($USD399.57K).

Tazminat ve Kazançlar: Lele's compensation has increased whilst the company is unprofitable.

CEO

Lele Zhang (47 yo)

5.2yrs

Görev süresi

CN¥50,602,000

Tazminat

Ms. Lele Zhang is founder of Cutia Therapeutics. She serves as Director of Cutia Therapeutics since May 12, 2020 and serves as ts Executive Director since November 15, 2022. Ms. Zhang has been CEO of Cutia...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Lele Zhang	Founder	5.2yrs	CN¥50.60m	0.0092% HK$ 339.8k
Yuqing Huang	CFO & Executive Director	3.5yrs	CN¥16.72m	0.028% HK$ 1.0m
Qi Zhu	Chief Medical Officer	5.2yrs	Veri yok	Veri yok
Lei Lei	Senior Vice President of Research & Development Department	2.2yrs	Veri yok	Veri yok
Chunna Zhang	Senior Vice President of Regulatory Affairs Department	2.2yrs	Veri yok	Veri yok
Jingxin Xu	Senior Vice President of Manufacturing & Quality Control Department	2.8yrs	Veri yok	Veri yok
Jiaru Wu	Senior Vice President of Finance & Integrated Management Department	2yrs	Veri yok	Veri yok
Sze Ting Chan	Company Secretary	2yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

43.5yo

Ortalama Yaş

Deneyimli Yönetim: 2487's management team is considered experienced (2.5 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Lele Zhang	Founder	4.5yrs	CN¥50.60m	0.0092% HK$ 339.8k
Yuqing Huang	CFO & Executive Director	2yrs	CN¥16.72m	0.028% HK$ 1.0m
Lian Yong Chen	Non-Executive Chairman of the Board	5.3yrs	Veri yok	Veri yok
Ming Kit Chung	Independent Non-Executive Director	1.5yrs	CN¥201.00k	Veri yok
Yunxia Yang	Non-Executive Director	4.3yrs	Veri yok	Veri yok
Qin Xie	Non-Executive Director	5.3yrs	Veri yok	Veri yok
Xiao Huang	Non-Executive Director	4.3yrs	Veri yok	Veri yok
Tak Yan Tao	Independent Non-Executive Director	1.5yrs	CN¥201.00k	Veri yok
Xiaoxiang Ye	Independent Non-Executive Director	1.5yrs	CN¥201.00k	Veri yok

4.3yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2487's board of directors are considered experienced (4.3 years average tenure).

Cutia Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CFO & Executive Director recently bought HK$422k worth of stock

CFO & Executive Director recently bought HK$460k worth of stock

Cutia Therapeutics, Annual General Meeting, Jun 05, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

CFO & Executive Director recently bought HK$422k worth of stock

CFO & Executive Director recently bought HK$460k worth of stock

Cutia Therapeutics Announces All Enroll Patients Completes Phase II Clinical Trial of CU-20401

Cutia Therapeutics announces First Patient Enrolled in the Phase I Clinical Trial of CU-10101 (Topical Novel Small Molecule Agent)For Atopic Dermatitis

Now 21% overvalued after recent price rise

First half 2024 earnings released: CN¥0.66 loss per share (vs CN¥15.84 loss in 1H 2023)

Does Cutia Therapeutics (HKG:2487) Have A Healthy Balance Sheet?

Cutia Therapeutics Announces Results of Phase III Clinical Trial of Cu-40102 (Topical Finasteride Spray) in the PRC Accepted for E-Poster Presentation

Cutia Therapeutics to Report First Half, 2024 Results on Aug 29, 2024

Now 45% undervalued after recent price drop

Cutia Therapeutics Announces Drug Marketing Authorization Application for CU-30101 (Localized Topical Lidocaine and Tetracaine Cream) Accepted by the National Medical Products Administration

New minor risk - Share price stability

Cutia Therapeutics Announces Results of Phase III Clinical Trial of Cu-10201 (Topical 4% Minocycline Foam) in the PRC Published Online in the Journal of the European Academy of Dermatology and Venereology

Cutia Therapeutics (SEHK:2487) commences an Equity Buyback for 30,473,862 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2024.

Cutia Therapeutics (SEHK:2487) commences an Equity Buyback for 30,473,862 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2024.

Now 43% undervalued after recent price drop

Cutia Therapeutics Announces Last Patient Enrollment in the Phase II Clinical Trial of Cu-20401

Now 23% undervalued after recent price drop

A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487)

Cutia Therapeutics Announces Investigational New Drug Application of CU-10101 for Atopic Dermatitis Approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC

Cutia Therapeutics, Annual General Meeting, Jun 05, 2024

Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week

Consensus revenue estimates increase by 40%, EPS downgraded

No longer forecast to breakeven

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration

Cutia Therapeutics to Report Fiscal Year 2023 Results on Mar 27, 2024

Consensus revenue estimates increase by 21%

Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401

Less than half of directors are independent

Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration

Forecast to breakeven in 2026

Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China

Cutia Therapeutics Announces Phase I Clinical Trial of Cu-20401 Abdominal Adipose Accumulation Completes Database Lock

Cutia Therapeutics Announces Phase I Clinical Trial of Cu-20401 Abdominal Adipose Accumulation Completes Database Lock

Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) in China Reached Primary Endpoint

Cutia Therapeutics Announces All Enrolled Patients Completes Phase I Clinical Trial of CU-20401

Cutia Therapeutics Announces New Drug Application for CU-10201 (Topical 4% Minocycline Foam) Accepted by the National Medical Products Administration

First half 2023 earnings released

New minor risk - Profitability

Cutia Therapeutics Announces Registrational Phase III Clinical Trial of the Group's CU-40102 Conducted in China for the Treatment of Androgenetic Alopecia Reached Primary Endpoint

Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) Completed Database Lock

Cutia Therapeutics Completes Phase Iii Clinical Trial of Cu-30101

Cutia Therapeutics to Report First Half, 2023 Results on Aug 29, 2023

Cutia Therapeutics Announces CU-10201 (Topical 4% Minocycline Foam) Granted Priority Review Designation by the Center for Drug Evaluation of the National Medical Products Administration

Less than half of directors are independent

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş